Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Foster City, California and currently employs 349 full-time employees. The company went IPO on 2019-07-18. The firm is focused on the treatment of rare diseases affecting children and adults. The company has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal or Ctexli (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. The firm is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.
Follow-Up Questions
Mirum Pharmaceuticals Inc 的 CEO 是誰？
Mr. Christopher Peetz 是 Mirum Pharmaceuticals Inc 的 Chief Executive Officer，自 2018 加入公司。
MIRM 股票的價格表現如何？
MIRM 的當前價格為 $73.53，在上個交易日 decreased 了 0%。
Mirum Pharmaceuticals Inc 的主要業務主題或行業是什麼？
Mirum Pharmaceuticals Inc 屬於 Biotechnology 行業，該板塊是 Health Care
